Abstract: Apparatus for repeated automatic execution of a thermal cycle for the treatment of a sample, especially a biological sample, comprises means (6) defining a pathway which is physically closed throughout the treatment and within which the sample is resident throughout the treatment. Means (3, 4, 11, 12) are provided to move the sample between different positions along the pathway and (7, 15, 16) to heat or cool the sample as a function of its position within the pathway. Preferably the pathway is a capillary tube, which may be in spiral, closed loop or linear form. Heating and cooling means are provided by thermostated zones which may provide a continuous thermal gradient regular or irregular, or be in a discontinuous arrangement. The preferred means of moving the samples is magnetic.

Abstract: The invention relates to pyrrolo-pyridine derivatives of the formula: ##STR1## wherein R represents a phenyl group, optionally substituted by one or more of various groups and therapeutically acceptable salts of these compounds, to a preparation process of the same comprising reacting, in an inert atmosphere and in a protic solvent, the 2-methyl 3-hydroxy 4,5-diboromomethyl pyridine, on a stoichiometric excess of the compound of the formula NH.sub.2 -R.The invention relates also to therapeutic compositions containing said derivatives as active ingredient.The compounds according to the invention have antiallergic activity.

Abstract: A method for inhibiting blood vessel blockage in a mammal particularly after a procedure such as angioplasty, an arterial bypass operation or an allograft transplant operation which comprises: administering to a mammal before, during and/or after the procedure an effective blood vessel blockage inhibiting amount of an octapeptide having the formula ##STR1## wherein each A.sub.1 and A.sub.2, independently, is H, C.sub.1-12 alkyl, C.sub.7-10 phenylalkyl, R.sub.1 CO (where R.sub.1 is C.sub.1-20 alkyl, C.sub.3-20 alkenyl, C.sub.3-20 alkinyl, phenyl, naphthyl, or C.sub.7-10 phenylalkyl), or R.sub.2 OCO (where R.sub.2 is C.sub.1-10 alkyl or C.sub.7-10 phenylalkyl), provided that when one of A.sub.1 or A.sub.2 is R.sub.1 CO or R.sub.2 OCO, the other must be H; A.sub.3 is CH.sub.2 A.sub.6 (where A.sub.6 is pentafluorophenyl, naphthyl, pyridyl, or phenyl); A.sub.4 is o-, m- or, more preferably, p-substituted X-Phe (where X is a halogen, H, NH.sub.2, NO.sub.2, OH , or C.sub.1-13 alkyl), pentafluoro-Phe, or .beta.

Abstract: The invention relates to 3-(N-methyl-N-alkyl)-amino 2-methoxymethylene propan 1-ol derivatives of the formula ##STR1## wherein R stands for an alkyl chain, A stands for: ##STR2## and Y represents various quaternary ammonia, to a preparation process of said compounds and to therapeutic compositions containing the same.

Abstract: The invention relates to glycerol derivatives of general formulae Ia, Ib and Ic ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, A and Y stand for various substituents, to a preparation process of said compounds and to therapeutical compositions containing the same.

Abstract: The invention relates to peptides having the general formulaH.sub.2 N - W - Ser - Asp - Lys - X - OHwherein X represents a Pro or Lys residue or a valence bond and W represents a Thr or Pro residue or a valence bond with the proviso that if X represents a Pro residue then W also represents a Pro residue; to a process for the preparation of the same and to therapeutic compositions containing said peptides.

Abstract: The invention relates to a therapeutical composition of matter for the treatment by perfusion of shock states comprising as an essential ingredient therein, an effective amount either, of a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.4 stant for H or CH.sub.3 or C.sub.2 H.sub.5,R.sub.2 stands for H or NO.sub.2 andR.sub.3 stands for NHR.sub.4 or CH.sub.3 or C.sub.2 H.sub.5alone or of a mixture of said compound with a cyclooxygenase blocker.

Abstract: The invention relates to new selenophen derivatives of the formulae, ##STR1## to a preparation process of said compounds and to therapeutic compositions containing the same.

Abstract: This invention relates to thieno-triazolo-diazepine derivatives of the formula ##STR1## wherein R represents various substituents, to a preparation process of these compounds consisting in reacting the thieno-triazolo-diazepine compound of the formula ##STR2## on RSO.sub.2 Cl and to therapeutic compositions containing the same. The compounds are particularly interesting as anti-PAF and anti-ischemic agents.

Abstract: The invention relates to thieno-triazolo-diazepine derivatives of the formula ##STR1## wherein Y stands for oxygen or sulphur and R stands for various substituents, to a preparation process of said compounds and to therapeutic compositions containing the same. The compounds are particularly interesting in the treatment of ischemia.

Abstract: This invention relates to a method for the separation of stereoisomers of 7-hydroxy-furo[3,4-c]pyridine derivatives of the formula ##STR1## wherein R.sub.3, R.sub.4 and R.sub.6 represent various substitutents, which comprises reacting a fully O-acetylated monosaccharide halogenide with a racemate of the selected 7-hydroxy-furo[3,4-c]pyridine derivative, to form the (+) and (-) (O-acetylated monosaccharide) (furo[3,4-c] pyridine 7-yl derivative) ethers, then separating the (+) and the (-) ethers by selective crystallization, in an hydroalcoholic medium, either of the acetylated forms or of the corresponding desacetylated forms and, finally, working up each of the separated derivatives by the usual routes. The compounds are known pharmaceuticals.

Abstract: The invention relates to a method for the preparation of a non-racemic furo [3,4-c] pyridine derivatives of the formula I ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 stand for various substitutents, comprising adding a concentrated strong acid to a solution of a non-racemic compound of the formula II ##STR2## in an amount sufficient to catalyze a deprotection/cyclodehydration. These compounds are known antihypertensives.

Abstract: This invention relates to piperazine derivatives of the general formula I ##STR1## wherein --(CH.sub.2).sub.n -- represents a straight or branched chain alkyl group having from n=1 to n=20 carbon atoms, and R represents a hydrogen atom, a branched alkyl group, a cycloalkyl group having from 5 to 10 carbon atoms, a phenyl group, optionally substituted by one or several chlorine atoms, methyl or methoxy groups, or straight or branched chain alkenyl groups having from 3 to 11 carbon atoms, to a preparation process of said compounds and to therapeutic compositions containing them as an active ingredient.

Abstract: This invention relates to new tetrahydrofurans and tetrahydrothiophenes of the general formula ##STR1## wherein X stands for O or S, .eta. is an integer from 1 to 6, R stands for various hydrocarbon substituents and Z.sup..crclbar. is a pharmaceutically acceptable anion, to a preparation process of said compounds and to therapeutic compositions of matter containing the same.

Abstract: This invention relates to catechol derivatives having the general formula ##STR1## wherein R represents various substituents, to a process for the preparation of the same comprising reacting S-(3,4-dihydroxyphenyl)-isothiourea, which has the formula II, with a tosylate of the general formula III ##STR2## and to therapeutical compositions wherein the active ingredient is one of these compounds.

Abstract: A living tissue or living cell preservation solution comprising an effective amount of a ginkgolide to reduce reperfusion injury in living tissue which has been stored therein and a substance or mixture or substances present in an amount sufficient to produce an osmotic pressure in said solution approximately equal to the osmotic pressure or mammalian cell and a method for preventing or reducing reperfusion injury in transplanted mammalian organs, which comprises contacting an organ prior to reperfusion with an effective amount of a ginkgolide to reduce reperfusion injury in said organ.

Abstract: An anti-diarrhea composition comprises diarrhea symptom-reducing amounts of a powdered absorptive material capable of absorbing pathogenic intestinal bacteria, a sodium salt, a potassium salt and a sugar. The absorptive material may be Smectite or mormoiron attapulgite. The salts are preferably NaCl and KCl, with NaHCO.sub.3 also being present. Suitable sugars are glucose and dextrose. The composition may also contain a suspending agent, a coloring agent, a flavoring agent and a sweetening agent. It may be packaged in solid form for admixture with water prior to administration and is preferably moisture protected, for example by the nature of the packaging or by inclusion of a dessicant. The absorptive material may be packaged separately from the salts and sugar. On admixture with water for adminstration, the composition preferably contains, per liter, 2.5 to 15 g of absorptive material, 10 to 30 g of glucose, 60 to 120 mEq of Na.sup.+, 10 to 50 mEq of HCO.sup.- and 10 to 30 mEq of K.sup.+.

Abstract: This invention relates to a process of preparation of nucleotide polymers wherein a lysate of a bacterial culture is passed successively through three columns (ion exchange resin, hydrophobic resin and molecular sieve), whereby there is obtained a substantially pure polynucleotidephosphorylase solution.Polymerization of this agent leads to non toxic and non pyrogen products.This invention relates also to products thus obtained and to therapeutic compositions containing the same.

Abstract: This invention relates to piperazine derivatives having the general formula I: ##STR1## wherein Y stands for ##STR2## and Z represents various substituents, to a preparation process of said compounds and to therapeutic compositions containing them as an active ingredient.

Abstract: The invention relates to new aminoacylates of glycerol acetal of the general formula I ##STR1## wherein R.sub.1 represents a substituted phenyl group or a group of the formula C.sub.m H.sub.2m+1, m being an integer of from 9 to 25,R.sub.2 represents a hydrogen atom, a phenyl group or a group of the formula C.sub.n H.sub.2n+1, n being an integer of from 1 to 10,p is a integer of from 3 to 10, ##STR2## represents a nitrogen containing heterocyclic group and X.sup..crclbar. means a pharmaceutically acceptable anion to a preparation process of said compounds and to therapeutic compositions of matter containing the same.